On June 1st, the Hong Kong-listed Aimei vaccine announced that the recently developed mRNA vaccine for the Omicron BA.5 variant of the novel coronavirus (LVRNA012) has completed mid-term analysis of crucial data on its protective efficacy and safety conducted by researchers in China, with the main result showing a maximum protection rate of 80.68%.

On June 1st, Aimei Vaccine announced the mid-term analysis of the protective efficacy and safety of the self-developed Omicron BA.5 mRNA vaccine in China, showing that the highest protective efficacy reached 80.68%.

On the morning of May 16th, the first pilot project in Guangdong, the "Spark Project" for eradicating the hazards of viral hepatitis in Jun'an Town, Shunde District, Foshan City, was officially launched. As a manufacturer of hepatitis B vaccines, Amyson Vaccine Co., Ltd. donated 40,000 doses of hepatitis B vaccine on-site.

Jia Shaojun, Executive President and Board member of AIM Vaccine, said that technological innovation is also one of the driving forces for the development of vaccines companies. AIM Vaccine needs to have one or more well-received products in the pursuit of a great company and great companies can only be made by great products. Both the company’s confidence and motivation lie in this belief.

AIM Vaccine announced that its upgrade product, bivalent Delta+Omicron BA.5 COVID-19 mRNA vaccine, has been officially approved for Phase III clinical trial in Pakistan.

Domestic leader in mRNA vaccine development, AIM Vaccine (06660.HK), is fully prepared to drive the upgradation of COVID-19 vaccines. According to the company's latest announcement, its bivalent Delta+Omicron BA.5 mRNA vaccine has been approved for Phase III clinical trial in Pakistan. Previously conducted clinical studies in China have proved good safety. Outcomes of virus neutralization assay showed that the vaccine candidate can induce high levels of neutralizing antibodies against Delta, Omicron BA.5, BQ.1 and XBB variants of SARS-nCoV-2.